At the core of the initiative is the CL1 biological computer developed by Cortical Labs, an Australian biotechnology company.

Early recognition of cognitive decline in primary care allows for improved management of mild cognitive impairment and dementia in aging populations.

Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), announced that the ...

Assisted reproductive technologies (ART) have become an integral component of infertility care worldwide. Alongside their widespread clinical use, growing ...

Bipolar disorder (BD) is a major mental disorder, affecting 1% of the global population. Patients suffering from BD ...

TAIPEI, Feb. 7, 2026 /PRNewswire/ -- Lumosa Therapeutics (Lumosa; 6535.TWO) today announced positive results from two independent Phase 2 clinical trials with its novel stroke drug LT3001 (Odatroltide ...

Maxim Group LLC acted as the exclusive financial advisor to Polaryx in connection with the direct listing. Gibson, Dunn & Crutcher LLP served as legal advisor and Brownstein Hyatt Farber Schreck, LLP ...

According to DelveInsight's analysis, the primary sclerosing cholangitis market is anticipated to grow during the forecast period (2025--2034), driven by the launch of emerging therapies such as LB-P8 ...

Global Mice Model Market OverviewThe global mice model market is projected to grow at an approximate rate of 9% over the next five years, supported by increasing demand for personalized medicine, ...

The intricate relationship between diet, metabolic disorders, and cancer progression has garnered significant attention in recent years. Excessive calorie intake is known to trigger the production of ...

Polaryx Therapeutics ("Polaryx" or the "Company") a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, ...

“In GA, light is not transduced into electrical signals because of a loss of photoreceptors, which leads to an absolute scotoma (blind spot). 2,3 The PRIMA neurostimulation system replaces the lost ...